International [U.S COVID Vaccine News] CDC to Lift COVID-19 Testing Requirement for international Travelers

It’s a gamble. I’m seeing people in their 30s dying from it. Granted they are usually overweight. But if your gonna be lazy and not lose the weight then you really need to get vaccinated.

Completely agree... every person should make a decision based on their own best interest. Preferably after talking to their doctor.

Why? Because maybe that severely obese person has health issues that may be exacerbated by the vaccine. Like heart issues?

Yeah... but fuck medical exemptions... lol
 


This is fucking idiotic.... There's several vaccines that the FDA tells women not to take while pregnant.

How many of these stories go unreported? Guarantee they're not making it into VAERS.


Incredible. More than a year later and you seems to STILL don't understand how VAERS works, much less what the "V-SAFE" registry mentioned in the studies actually is, or the fundamental differences between Correlation and Causation. Do you still hang out in goldenwolf's anti-vax thread and trade these meme photos posted by absolute nobodies from Twitter instead of reading actual medical papers on the subject matter or something? o_O

Here is a somber scientific facts: Miscarriages in humans are actually quite high. Between 10% to 26% of all known pregnancies ends in miscarriages, most of which occurs in the First Trimester. This is not breaking news to adults who could read.

The real news here is that while the number of miscarriages in Vaccinated expectant mothers (less than 13%) DID NOT increase anymore than the norm, nearly all (97%) of the pregnant women who DID ended up in the ICU (with their unborn child in tow) because of Covid were Unvaccinated. Do you have the reading-comprehension capability to understand what that actually means?

Lastly, the previously-posted study from the New England Journal of Medicine included data from both V-Safe (the pregnancy outcomes reporting tool for pregnant mothers) as well as VAERS (the side-effects self reporting tool for everyone). Once again, these facts are only well-known to people who are capable of reading actual medical studies written by actual scientists, instead of getting their anti-vax "guarantees" from the absolute Nobodies on Twitter.

What are you, an idiot? How many fucking kids have been born through the process and how much long term study do we have on them? Oh right, less than a year at best.

The V-Safe births/miscarriages data in the studies are reported by the moms within the year, primarily because human pregnancies generally lasts around 9 months or less. Surprised at how that works?

The unborn children themselves aren't vaccinated, they get their antibodies from their vaccinated mothers, which protects them in the short term, just like flu shots. Surprised at how that works?

Again: Which of the three aforementioned scientific studies on miscarriage risks have you actually read, and which of the presented data do you disagree with exactly, anti-vax genius?

If actual science isn't your cup of tea, get the fuck back to the anti-vax thread with the rest of the crazies to push your miracle cures instead. I'm sure the "proven" quackeries that you lot swears by have all studies and data that you need to continue prolonging this pandemic.
 
Last edited:
Trees native to Chile hold hope for Novavax's Covid-19 vaccine — will there be enough?
Two molecules made from from the Quillay tree are ingredients in a new Covid-19 vaccine that could produce billions of doses for low- and middle-income countries.
By REUTERS • Oct. 6, 2021
211006-Quillay-soapbark-tree-se-1104a-73bdfa.jpg

CASABLANCA, Chile — Down a dusty farm track in Chilean wine country, behind a wooden gate wrapped in chains, forestry experts are nursing a plantation of saplings whose bark holds the promise of potent vaccines.

Quillay trees, technically known as Quillaja saponaria, are rare evergreens native to Chile that have long been used by the indigenous Mapuche people to make soap and medicine. In recent years, they have also been used to make a highly successful vaccine against shingles and the world’s first malaria vaccine, as well as foaming agents for products in the food, beverage and mining industries.

Now two saponin molecules, made from the bark of branches pruned from older trees in Chile’s forests, are being used for a COVID-19 vaccine developed by drugmaker Novavax Inc (NVAX.O). The chemicals are used to make adjuvant, a substance that boosts the immune system.

Over the next two years, Maryland-based Novavax (NVAX.O) plans to produce billions of doses of the vaccine, mostly for low- and middle-income countries, which would make it one of the largest COVID-19 vaccine suppliers in the world.

With no reliable data on how many healthy quillay trees are left in Chile, experts and industry officials are divided on how quickly the supply of older trees will be depleted by rising demand. But nearly everyone agrees that industries relying on quillay extracts will at some point need to switch to plantation-grown trees or a lab-grown alternative.

A Reuters analysis of export data from trade data provider ImportGenius shows that the supply of older trees is under increasing pressure. Exports of quillay products more than tripled to more than 3,600 tonnes per year in the decade before the pandemic.

Ricardo San Martin, who developed the pruning and extraction process that created the modern quillay industry, said producers must immediately work toward making quillay products from younger, plantation-grown trees.

“My estimate four years ago was that we were heading towards the sustainability limit,” he said.

San Martin said he has toiled through the COVID-19 pandemic in the basement of his oceanfront cabin in Sea Ranch, California, to refine a process that could help produce saponins from leaves and twigs in order to maximize the yield.

“I am working as though this needs to be done yesterday,” said San Martin, who is also sponsoring a project in which drones would count quillay trees in remote and hard-to-access forests, to determine how many are left.

Quillay producers and their customers say the harvest can continue for now without decimating the supply of older trees.

“We continue to monitor the situation in Chile, in close collaboration with our supplier, but at this time we are confident in our supply,” Novavax said in a statement to Reuters. The company also said it was confident that uses such as “life-saving vaccines will be prioritized.”

The desert-plant extract company Desert King International Ltd, which runs the Casablanca plantation, is Novavax’s sole supplier of quillay extracts and Chile’s largest quillay exporter by far.

The company’s manager in Chile, Andres Gonzalez, told Reuters it is set to produce enough quillay extract from older trees to make up to 4.4 billion vaccine doses in 2022. With new supplies from privately owned native forests, they have enough raw material to meet demand for the rest of this year and part of next, he said.

Gonzalez said the company, where San Martin is a consultant, has built a new production plant and has the capacity to supply other interested pharmaceutical firms — all without harming the forests.

He acknowledged, however, that “at some point these native forests will come to an end.”

“We want to start having very productive plantations, and we are working on that,” he said.

A relatively small volume of quillay extract is required to make vaccines — just under one milligram per dose — but the supply is stretched by the demand from other industries. Quillay products are used, for instance, as a natural additive in animal feed, a biopesticide and an agent to reduce pollution in mining.

Individual quillay trees grow outside of Chile, but Chile is the only country where mature quillay is harvested from forests in large quantities.

An elusive ingredient
Novavax’s adjuvant, known as Matrix-M, contains two key saponin molecules. One of those, called QS-21, is more difficult to access because it is found mainly in trees that are at least 10 years old.

Among major pharmaceutical companies, only GlaxoSmithKline PLC (GSK.L) and Novavax have bet heavily on QS-21, a relatively new pharmaceutical ingredient.

GSK’s highly successful vaccine against shingles, Shingrix, and several other promising experimental vaccines contain QS-21 supplied by Desert King. In a statement, GSK said it has “no specific challenges relating to sustainable supply” of QS-21.

The quillay-based adjuvant used in Shingrix is also part of the world’s first malaria vaccine, Mosquirix. Despite low efficacy, it was approved by European regulators in 2015 and recommended for pilot introduction by the WHO in 2016 because of dire need.

No other COVID-19 vaccine manufacturers are relying on quillay bark extracts. Some drugmakers are developing synthetic alternatives, but these could be years from regulatory approval. Switching out the ingredients in any existing vaccine would require new clinical studies to prove the product is safe and effective.

The Massachusetts-based pharmaceutical company Agenus stopped selling bark-derived QS-21 several years ago to focus full-time on trying to grow it from quillay plant cells in a laboratory.

“The shortage of QS-21 has been an issue for a while,” said Jason Paragas, Agenus vice president of strategic initiatives and growth exploration. “We saw it before COVID, and we made the hard decision that we had to change.”

Paragas said it is too soon to say when an alternative could be ready.

Entrepreneur Gaston Salinas said his Davis, California-based startup Botanical Solution Inc can already produce QS-21 from quillay tissue starting with seeds in the lab, and aims to eventually produce the chemical on a large scale to supply pharmaceutical companies.

“You cannot afford to over-exploit the native Chilean forest because of a desire to develop modern vaccines. You need to find other ways to develop your products, even if it’s something so important, ” he said.

An eye toward the future
Inside the gate of the carefully guarded Desert King plantation, gardeners carefully tend to the young trees using fertilizers and bountiful supplies of water. They were cloned from full-grown cousins whose dusty gray bark was especially rich in saponins.

If all goes well, the plantation could be producing for one customer in two to three years, according to Desert King’s business development manager Damian Hiley. He declined to name the company.

Desert King has its eye on future vaccines, some already in the works.

In early 2020, for instance, GSK licensed an experimental tuberculosis vaccine that contains GSK’s QS-21-based adjuvant to the Bill and Melinda Gates Medical Research Institute. It showed promising results in a mid-stage trial.

And in April, researchers at Oxford University announced that a new malaria vaccine containing Novavax’s Matrix-M adjuvant appeared to be highly effective in a trial involving 450 children in Burkina Faso.

Gustavo Cruz, a researcher at the University of Chile who worked with San Martin to industrialize production of quillay, said he generally trusts quillay producers to manage supply and demand. He is more worried about other threats — specifically drought and fire.

“The trees do eventually regrow,” he said, “but there comes a time when they don’t anymore.”
https://www.nbcnews.com/news/amp/rcna2647
 
Pfizer, BioNTech seek U.S. COVID-19 vaccine clearance for children 5-11
By Reuters | Oct 7, 2021



WASHINGTON, Oct 7 (Reuters) - Pfizer Inc and BioNTech SE have asked U.S. regulators to authorize emergency use of their COVID-19 vaccine for children ages 5 to 11, a group for whom no shot is currently allowed, Pfizer said on Thursday.

The U.S. Food and Drug Administration has set a date of Oct. 26 for its panel of outside advisers to meet and discuss the application, making it possible for children in this age group - numbering around 28 million - to begin receiving the two-dose Pfizer/BioNTech vaccine shortly afterward.

"With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19," Pfizer wrote on Twitter.

The vaccine already has won U.S. emergency use authorization in teens ages 12 to 15 and is fully approved by regulators for people ages 16 and up.

The Pfizer/BioNTech vaccine is one of three in use in the United States, along with the two-dose Moderna (MRNA.O) vaccine and the single-dose Johnson & Johnson (JNJ.N) version, neither of which has won full regulatory approval for any age group.

A rapid authorization of the Pfizer/BioNTech vaccine in young kids could help mitigate a potential surge of cases in the coming weeks and months, with schools open nationwide and colder weather driving activities indoors. If given regulatory authorization, the two-dose Pfizer/BioNTech vaccine would become the first COVID-19 shot made available to children 5 to 11 in the United States.

The Pfizer/BioNTech vaccine has been shown to induce a strong immune response in 5 to 11 year olds in a 2,268-participant clinical trial, the companies said on Sept. 20. read more

The two drugmakers are also testing the vaccine in children ages 2 to 5 years old and children ages 6 months to 2 years, with data expected in the fourth quarter.


The vaccine could be ready for roll out as early as November pending approval from federal regulatory health agencies, White House COVID-19 response coordinator Jeffrey Zients said on CNN.

Once the authorization is granted, Zients said: "We are ready. We have the supply. We're working with states to set up convenient locations for parents and kids to get vaccinated including pediatricians' offices and community sites."

The United States leads the world in COVID-19 cases and deaths.

Children currently make up about 27% of all U.S. coronavirus cases and an increasing percentage of hospitalizations, according to the American Academy of Pediatrics. That reflects the high contagiousness of the coronavirus Delta variant among unvaccinated people.

While children are less susceptible to severe COVID-19, they can spread the virus to others, including vulnerable populations more at risk of severe illness.

A Pfizer spokesperson said the application to the FDA has been completed.

https://www.reuters.com/world/us/pf...gulators-ok-covid-19-vaccine-kids-2021-10-07/
 
Last edited:
FDA vaccine advisers are meeting to consider Moderna's vaccine booster for high-risk groups
Jamie Gumbrecht | October 14, 2021



Vaccine advisers to the US Food and Drug Administration are meeting Thursday morning to discuss whether to authorize boosters of Moderna's coronavirus vaccine for some adults.

It's the first portion of a two-day Vaccines and Related Biological Products Advisory Committee meeting that will also include a vote on boosters for the Johnson & Johnson vaccine and a presentation on mix-and-match vaccines. Thursday's agenda focuses on Moderna boosters, and includes a presentation by Moderna, and another by the FDA, which will provide its assessment of Moderna's booster data.

Moderna is requesting authorization for a 50-microgram booster dose -- half the size of the 100-microgram doses used in the primary series of the two-dose vaccine -- at least six months after the second dose, and only for certain groups: people age 65 and older; people ages 18 to 64 who are at high risk of severe Covid-19; and people ages 18 to 64 whose exposure to the coronavirus in their settings or jobs put them at risk for Covid-19 complications or severe illness.

Moderna's request mirrors the groups authorized to receive a booster dose of Pfizer's mRNA vaccine. Third doses of the Moderna and Pfizer Covid-19 vaccines are already authorized for some immunocompromised people.

The FDA's committee of independent advisers typically discusses and makes recommendations to the agency around vaccine authorizations and approvals, and the agency then makes the final decision about whether to OK a vaccine. If the FDA gives emergency use authorization to Moderna boosters, vaccine advisers to the US Centers for Disease Control and Prevention will meet to discuss which groups to recommend them to. Typically, shots can be administered once the CDC director signs off on the recommendation.

https://amp.cnn.com/cnn/2021/10/14/health/fda-vaccine-advisers-moderna-thursday/index.html
 
Last edited:
Moderna’s vaccine efficacy held strong, did not wane after 5 months, new study shows
By Alexi Cohan | September 23, 2021



Coronavirus protection offered by Moderna’s mRNA vaccine held strong and did not wane for more than five months after the second shot, a new study out of Brigham and Women’s Hospital shows.

In a study of more than 30,000 participants, the vaccine remained safe and effective for an average of 5.3 months after their second shot. Even after the time had passed, the shot was 93.2% effective in preventing illness from COVID-19, and 98.2% effective in preventing severe disease.

Strong protection remained in all subgroups including elderly participants and those with comorbidities. Researchers also found there was protection against asymptomatic coronavirus.

Dr. Lindsey Baden, infectious disease specialist at BWH and co-corresponding author of the research published Wednesday in the New England Journal of Medicine said, “Overall, our results continue to demonstrate that vaccines work and work extremely well at preventing COVID-19.”

Baden said, “We are continuing to explore questions about duration of immunity following vaccination and the impact of variants. But even as we examine the possibility of waning immunity, we see evidence that the vaccine is still very protective.”

https://www.ocregister.com/2021/09/...-did-not-wane-after-5-months-new-study-shows/


Cliff: Most younger people who got the Moderna vaccine don't actually need boosters, as the enduring protection from their immunization still remains well over 90% effective against severe COVID infections and hospitalization half a year later.

High-risk groups that might want to consider getting the half-dose booster:
  • Seniors age 65 and older (protection in the elderly is now at 80%).
  • People with serious medical conditions that would make them more vulnerable to infections.
  • People with high risk of exposure to the coronavirus at work.
-----

FDA panel recommend EUA for Moderna's half-dose vaccine booster for at-risk groups

Vaccine adviser rs to the US Food and Drug Administration voted unanimously Thursday to recommend emergency use authorization of a booster dose of Moderna's Covid-19 vaccine.

The FDA's Vaccines and Related Biological Products Advisory Committee agreed use of a booster dose would be safe and effective in some people six months out from their primary series.

Moderna had asked for emergency use authorization for a half dose of its vaccine to be used as a booster for certain people.

All 19 members of the committee supported authorizing a 50-microgram booster dose -- half the size of the 100-microgram doses used in the primary series of the two-dose vaccine -- at least six months after the second dose, and only for certain groups: people age 65 and older; people ages 18 to 64 who are at high risk of severe Covid-19; and people ages 18 to 64 whose exposure to the coronavirus in their settings or jobs put them at risk for Covid-19 complications or severe illness.

Moderna's EUA request mirrored the groups authorized to receive a booster dose of Pfizer's mRNA vaccine. Third doses of the Moderna and Pfizer Covid-19 vaccines are already authorized for some immunocompromised people.

Members of the committee said they were not entirely convinced the data showed a booster was necessary or that it increased protection.

"The data are not perfect but these are extraordinary times and we have to work with imperfect data," said Dr. Eric Rubin, editor-in-chief of the New England Journal of Medicine and a professor at the Harvard T.H. Chan School of Public Health.

"We can't afford to have health care workers, even if not sick, be positive and infected and have to stay home from work because in parts of the country there's a shortage of health care workers and there's burnout everywhere," said Dr. Stanley Perlman, a professor of pediatrics at the University of California San Diego.

The Vaccines and Related Biological Products Advisory Committee meeting will continue Friday, when members are expected to vote on boosters for the Johnson & Johnson vaccine, and will hear a presentation on mix-and-match vaccines.

The FDA's committee of independent advisers typically discusses and makes recommendations to the agency around vaccine authorizations and approvals, and the agency then makes the final decision about whether to OK a vaccine.

If the FDA gives emergency use authorization to Moderna boosters, vaccine advisers to the US Centers for Disease Control and Prevention will meet to discuss which groups to recommend them to. Typically, shots can be administered once the CDC director signs off on the recommendation.

CDC's Advisory Committee on Immunization Practices is already scheduled to discuss boosters on October 21.

https://amp.cnn.com/cnn/2021/10/14/health/fda-vaccine-advisers-moderna-thursday/index.html
 
Last edited:
While FDA scientists did say there may be a benefit from a second Johnson & Johnson shot two months after an initial dose, the agency noted the data is limited. It’s not clear whether these concerns would be enough to delay emergency use authorization.

 
F.D.A. Panel Unanimously Recommends Johnson & Johnson Booster Shots
But many panel members said J. & J. recipients might also benefit from the option of a Pfizer-BioNTech or Moderna booster, an action that an F.D.A. official said was possible.
By Sharon LaFraniere, Noah Weiland and Carl Zimmer | Oct. 15, 2021​


WASHINGTON — A key federal advisory committee voted unanimously Friday to recommend Johnson & Johnson booster shots, most likely clearing the way for all 15 million people who got the company’s one-dose coronavirus vaccine to receive a second shot.

If the Food and Drug Administration and the Centers for Disease Control and Prevention accept the recommendation, as expected, boosters could be offered by late next week. But many committee members made clear that they believed Johnson & Johnson recipients might benefit from the option of a booster of the Pfizer-BioNTech or Moderna vaccine, something a top F.D.A. official said the agency was considering.

With a series of votes over the past month to recommend boosters for all three coronavirus vaccines used in the United States, the panel set aside significant divisions and skepticism about whether extra shots are needed and edged ever closer to the goal that President Biden laid out in August when he called for boosters for all adults.

Well over 100 million fully vaccinated people will be eligible for boosters if the F.D.A. and C.D.C. endorse the committee’s latest recommendations, even though some scientists say that the evidence supporting boosters remains weak and that it would have been wiser to focus on reaching the unvaccinated, including abroad.

Johnson & Johnson’s vaccine took a beating at Friday’s session, as did the F.D.A. for pushing for a decision without verifying all of the data that the company had submitted.

But the panel members appeared swayed by the argument that it would be unfair to deny Johnson & Johnson recipients an additional shot after endorsing boosters for recipients of the other two vaccines, especially in the face of evidence that Johnson & Johnson offers the weakest protection of the three.

“There is a public health imperative here, because what we’re seeing is that this is a group with overall lower efficacy than we have seen with the mRNA vaccines,” said Dr. Arnold Monto, the committee’s acting chairman and a professor of epidemiology at the University of Michigan School of Public Health. “So there is some urgency there to do something.”

In its second successive day of discussion on boosters, the group wavered on whether it would be wise to soon offer extra shots to younger recipients of the Pfizer and Moderna vaccines.

The government’s strategy now is to offer boosters of those vaccines to people 65 and older and to younger adults at high risk because of their medical conditions or jobs. No decision was made about broader eligibility criteria, but Dr. Monto and others described the issue as increasingly pressing.

The panel also seemed intrigued by preliminary data suggesting that Johnson & Johnson recipients may be better off with a booster shot from Moderna or Pfizer. Although no vote was taken, Dr. Peter Marks, who oversees the F.D.A.’s vaccine division, said regulatory action to allow boosters with a different vaccine was “possible.”

While some experts emphasized that the data was based on small groups of volunteers and short-term findings, others urged the F.D.A. to move quickly with what has fast become known as a mix-and-match approach, especially for recipients of Johnson & Johnson’s vaccine, which is much less widely available.

“I’m sold already,” said Dr. Mark Sawyer, an infectious disease specialist with the University of California San Diego School of Medicine. “We need flexibility and to improve access to everyone.”

Others said they worried that the public would end up bewildered if the government kept broadening the categories of people eligible for boosters and which vaccine could be used for extra shots.

“I hope we can do this in a way that doesn’t look like we’re changing rules all the time,” said Dr. Stanley Perlman, a professor of immunology at the University of Iowa.

Health officials and committee members suggested on Friday that the single-shot Johnson & Johnson vaccine had long been less protective. In a particularly biting critique, Dr. Amanda Cohn, a high-ranking C.D.C. medical officer, said a single dose of Johnson & Johnson’s vaccine offered less protection than two doses of the mRNA vaccines made by Pfizer or Moderna — a gap that would only grow if it remained a one-shot regimen while the other two-shot vaccines were followed by a booster.

Dr. Marks emphasized that the one-shot, easily stored Johnson & Johnson shot had served partly as an “outreach” vaccine — suggesting that refusing to offer a booster would disadvantage vulnerable populations.

To date, more than 104 million people in the United States have been fully vaccinated with Pfizer’s product, more than 69 million with Moderna’s and about 15 million with the Johnson & Johnson shot.

The government decided last month to offer booster shots of Pfizer’s vaccine to older Americans and other high-risk groups, and the panel voted Thursday to recommend the same approach for Moderna recipients. More than eight million people in the United States have already obtained Pfizer booster doses, and about 1.6 million have received third doses of Moderna’s, even though only Moderna recipients with immune deficiencies are officially eligible.

For Johnson & Johnson recipients, the committee recommended an additional shot for everyone who had received the vaccine — a reflection of its lower efficacy. Although the added injection was cast as a booster, some experts on the committee argued that the vaccine should have involved two doses from the start, separated by about two months.

Johnson & Johnson officials said a second dose given either two or six months after the first shot increased antibody levels, part of the immune response to vaccines. They also said that unlike Pfizer’s vaccine, Johnson & Johnson’s potency did not wane significantly over time.

The experts generally agreed that the protection conferred by a single dose was inadequate, but at least some were unconvinced that the second dose would bolster that protection significantly.


They were critical of the company’s data, saying F.D.A. regulators had challenged the sensitivity of one key test used to measure antibodies in people who received booster doses. They balked at the size of a study on Johnson & Johnson booster doses given at a sixth-month interval, based on only 17 volunteers. And they were clearly distressed to see slide after slide of data with the huge caveat: “Not verified by F.D.A.”

Dr. Archana Chatterjee, the dean of the Chicago Medical School, pointedly asked why the F.D.A. was pushing for a decision without a thorough review.

But she said later that she was convinced by the totality of the data, especially a C.D.C. report that found Johnson & Johnson was only 71 percent effective against hospitalization, compared with 88 percent for Pfizer and 93 percent for Moderna.

Ahead lie still more decisions for the F.D.A. and its outside experts. The group is set to meet again this month to discuss Pfizer-BioNTech’s request for authorization of a lower dose of its vaccine in children 5 to 11. Also pending is a decision on whether to authorize Moderna’s vaccine for adolescents — a move complicated by conflicting data about possible side effects involving the heart.

Regulators are expected to soon consider whether to allow people to get boosters of a different vaccine than what they initially got, which might produce a stronger immune response. “It’s real-world, practical questions that people want to know,” said Dr. Kirsten Lyke of the University of Maryland School of Medicine, who presented the results of the mix-and-match study to the committee.

Preliminary findings showed Johnson & Johnson recipients who got a booster with the Moderna vaccine saw their antibody levels rise 76-fold within 15 days, compared with only a fourfold rise if they received a booster shot of Johnson & Johnson. A Pfizer-BioNTech booster raised antibody levels in Johnson & Johnson recipients 35-fold.

The trial only looked at antibody levels, which on their own are an insufficient measure of how well different combinations of vaccines would protect people.

Dr. Cohn, the C.D.C. official, suggested that the F.D.A. could include language in its booster authorizations that would allow switches between brands.

“From a public health perspective, there’s a clear need in some situations for individuals to receive a different vaccine,” she said. She said that some people might not have access to the same vaccine again, or might have increased risks of some side effects from using it again as a booster.

Dr. Ofer Levy, an infectious disease physician at Boston Children’s Hospital, said the F.D.A. should act because some people were already seeking boosters on their own.

“In the real world, all these kinds of combinations or extra boosters are already happening,” he said. “We can’t hide from it, and I do think we need to give guidance to the public.”

At the same time, the government needs “to make sure that we don’t confuse the public even more than we are already,” said Dr. Jeannette Lee, a professor at the University of Arkansas for Medical Sciences.

https://www.nytimes.com/2021/10/15/health/johnson-johnson-vaccine-booster.html

Cliff: The booster efficacy data that J&J presented is not very convincing at all because the study is TINY (a whopping 17 volunteers, and the FDA panel decided to recommend it purely because the protection from the original shot 6 months ago is pretty low now (71% effective against hospitalization, compared with 88% for Pfizer and 93% for Moderna).

Honestly, I wouldn't be surprised if a big chunk of previous J&J receipients might switch over to one of the two mRNA types instead.
 
Last edited:
Lol soon at risk goalpost will be ages 5 up… people who fall for this still are hopeless..

That would depends on how determined people are at unnecessarily prolonging this pandemic and allowing the virus to continue mutating even more, isn't it?

Real-world hospital data from every State, liberal or conservative, had already shown that Delta sent many more people under 60 to the ICUs than the original strain (that largely left the young adults alone), particularly the loud and proud anti-vax folks who believe it's "just the flu" up to the point they suddenly decided to trust in doctors as they are gasping for air, and ends up taking up hospital beds from other patients. So what's the point of grown adults sitting around waiting for a mutation that would send kids to the ICUs?

It's now been a year since America gave the world the best tools to wipe out this virus. We should be among the first to be free of COVID, like the Smallpox, Polio, and Measles before it. If it gets to the point that even 5 year old American kids would need boosters regularly to keep them away from the ICU's, then we are not much better than Third World countries where modern medical science is a pipe dream.
 
Last edited:
That would depends on how determined people are at unnecessarily prolonging this pandemic and allowing the virus to continue mutating even more, isn't it?

Real-world hospital data from every State, liberal or conservative, had already shown that Delta sent many more people between 21 and 60 to the ICUs than the original strain, particularly the loud and proud anti-vax folks who believe it's "just the flu" up to the point they suddenly decided to trust in doctors as they are gasping for air. So what's the point of sitting around waiting for a mutation that would send kids to the ICUs?

If it gets to the point that 5 year old American kids would need boosters to protect them from new mutations just like their parents, then we are no better than Third World countries where modern medical science is a pipe dream.
Wow since I returned back haven’t seen a single one of your posts you’ve certainly a changed your tune sorry to see you’re buying this fucking shit now…fucking sad actually.
 
F.D.A. Panel Unanimously Recommends Johnson & Johnson Booster Shots
But many panel members said J. & J. recipients might also benefit from the option of a Pfizer-BioNTech or Moderna booster, an action that an F.D.A. official said was possible.
By Sharon LaFraniere, Noah Weiland and Carl Zimmer | Oct. 15, 2021​




https://www.nytimes.com/2021/10/15/health/johnson-johnson-vaccine-booster.html

Lmfao you start working for big pharma since I was here last what a joke ..
 
Wow since I returned back haven’t seen a single one of your posts you’ve certainly a changed your tune sorry to see you’re buying this fucking shit now…

My view on this damn virus and the anti-vax idiots who insists on keeping it around for no good reason whatsoever hasn't changed one bit, especially after watching my own relatives ends up in the ICU last year before they got the chance to get immunized.

Or perhaps you've confused me for one of the "just the flu" bros who still believe Covid is a hoax and can easily be cured by hydroxychloroquine?

If that's what you seek, you can find the anti-vax knuckle-draggers pushing their latest conspiracy theories over in the Vaccine protest thread instead, and leave this one to actual Scientific News.
 
Last edited:
Stick your fucking vax up your ass either way , your posts are beyond pathetic they are stupid rhetoric…. Nobody is prolonging anything but the retarded government that declared everything covid including all influenza…

The flu most definitely did not put my own nephew in a coma for 3 days in the ICU, and I prefer to take my immunization shots in the forearm, like a normal person would.

Your preference for sticking things up your anus contribute very little to this Scientific News thread. Have you even read the OP yet before spamming your utter nonsense? That might explain your surprise to see the latest news on the FDA. o_O
 
Last edited:
Really disgusting guy

I remember he got some kind of soy meltdown in an earlier wu flu thread series and stopped posting entirely, and now he has re-emerged as an ultracucked pro-lockdown soy tyranny NPC that just spams corporate media article copy-pastes in his little soy thread. Very pathetic, but not surprising.
Yeah I see that wow.
 
Really disgusting guy

I remember he got some kind of soy meltdown in an earlier wu flu thread series and stopped posting entirely, and now he has re-emerged as an ultracucked pro-lockdown soy tyranny NPC that just spams corporate media article copy-pastes in his little soy thread. Very pathetic, but not surprising.
He's embracing science

NBD
 
Anti vaxers already have their echo chamber thread. Why do they feel the need to ruin this one?
 
The CDC's COVID-19 tracker previously shows the latest statistics on COVID cases and deaths based on vaccination status and age group, as reported by health departments across the country. Now the monthly stats is further broken down by the three vaccine types being used in the U.S as well.

Not surprisingly, J&J is not as strong as Pfizer and Moderna like everyone already knew, and there's still a massive gulf between those who are immunized vs those who have no protection at all, especially in the older age groups: a vaccinated 80 year old is safer than an unvaccinated 50 year old.
-----
CDC data confirms J&J is not as good as the mRNA vaccines — but being unvaccinated is far more dangerous
By Hilary Brueck | Oct 15, 2021

6169a97f38c1960018301a34

Source: Centers for Disease Control and Prevention

Two COVID-19 shots work better than one.

For the first time, the Centers for Disease Control and Prevention is sharing data from across the US on COVID-19 cases and deaths, broken down by vaccination status, as well as vaccine brand.

With this more granular data available, clear trends are emerging showing Pfizer and Moderna's two-shot vaccines work best at preventing all kinds of COVID-19 infections.

"Firstly, the vaccines work," immunologist John Moore from Weill Cornell Medical College told Insider, as he reviewed the new data. "The difference between vaccinated and unvaccinated is huge."

That's true. In August, the risk of catching COVID-19 was more than six times higher for unvaccinated people, according to the CDC's new graph.

Still, there's a "split in the potency of the vaccines with J&J and the other two," Moore said.

Moderna's vaccine (green line) seems to have the edge, while Johnson & Johnson's one-shot vaccine (in orange) isn't holding up as well.

J&J's single shot vaccine isn't as good as the others at preventing coronavirus infections. Part of the reason for the difference might be that one exposure to a pathogen isn't enough to stimulate a really robust immune response. (That's another reason why it's a good idea for people who've had COVID-19 to get vaccinated.)

Mounting evidence J&J should be a 2-shot vaccine

The data comes at a critical time, as an independent advisory committee to the US Food and Drug Administration voted unanimously Friday to support booster doses for everybody who's gotten J&J's vaccine.

At the meeting, Peter Marks, who directs the FDA's Center for Biologics Evaluation and Research, said "there is some concern" about "the idea of the Janssen [J&J] vaccine as one dose."

"All of the data do not fully align with this being a vaccine that retains excellent activity over time against all forms of disease, or even against severe forms of disease," Marks said.

Indeed, according to the new CDC charts, J&J's vaccine isn't protecting people against death in the same way that the other vaccines are. Fewer than one in every 100,000 people vaccinated with Pfizer or Moderna's vaccine have died from COVID-19, but for J&J, the number is roughly double that.

Dr. Amanda Cohn from the CDC told the FDA panel Friday that the real-world effectiveness of J&J's vaccine is "hovering" around 50-60% overall, and it is only 68% effective at keeping people out of the hospital, which is "substantially lower than the mRNA vaccines."

The risk of death for fully vaccinated people under the age of 65 is virtually non-existent


Not everyone who's vaccinated has the same risk of death. Older adults don't mount as good of an immune response to vaccines as younger people do, while people over the age of 80 are especially vulnerable to severe disease, even if they are vaccinated.

"It's essentially unheard of for vaccinated people under 65 to die of COVID-19 after vaccination," Moore said.

The new CDC data shows that clearly, with the solid green, turquoise, and orange lines for vaccinated people under the age of 65 remaining flat.


Moore said younger people who've had the J&J vaccine still don't need to worry, even if they only have a single jab on board. His own son and his partner, both in their 30s, have had J&J.

"They're not panicking about it, and I'm not panicking about them," he said. Still, he added "I've always said right from the start that J&J is a two-dose vaccine."

While J&J recipients might need a second shot, it doesn't necessarily have to be the same brand. A recent mix-and-match study suggested that people who've had J&J may get a stronger boost from Pfizer or Moderna.

Dr. Penny Heaton, from Janssen's vaccine research and development team, told the FDA committee on Friday, "The bottom line is, single dose, you get a lower efficacy."

https://www.businessinsider.com/cdc-jj-vaccine-doesnt-protect-as-well-as-moderna-pfizer-2021-10
 
Last edited:
https://japantoday.com/category/national/unused-covid-shots-piling-up-in-japan-amid-slow-rollout Worth a read. Japan is going very very slowly with the roll out. I think most don’t actually want it and are dragging their feet on all fronts.

My wife says that they want a vaccine that will stop it 100% and until then this vaccine is pointless. Basically they want a fully effective one and are waiting for it. Plus many don’t like the side effects, which Japanese tend to get more so then other people

@ElKarlo Nice, Japan started super late during the 2nd wave but has now surpassed a lot of Western countries out there, including the U.S. I'm guessing there's no more state of emergency and life is returning to normal as infections and hospitalization dramatically dropped to all-time low?

Over 70% in Japan vaccinated against COVID-19

np_file_115949.jpeg

Slightly over 60% of people in Japan have received their second shot of a COVID-19 vaccine, the government said Monday.

According to the government, 60.9% of people have had their second dose, while 71.3% have received their first.

The proportion of fully vaccinated residents is expected to top 70% this month.

About 167 million vaccine doses had been administered as of the time of the data’s release, with over 90 million people having received their first shot and around 77 million their second.

Of those age 65 or older, 90.6% had received their first shot and 89.4% their second.

Currently, COVID-19 vaccines made by Pfizer Inc., Moderna Inc. and AstraZeneca PLC are administered in Japan.

About 140 million shots of the Pfizer vaccine had been administered to people since its approval in February, accounting for over 80% of the total doses.

Some 27 million shots of the Moderna vaccine, which was approved in May, and roughly 50,000 doses of the AstraZeneca vaccine had been given. Japan started using the AstraZeneca vaccine in August.

According to Our World in Data, the share of fully vaccinated people as of Thursday stood at 54.89% in the United States and at 63.99% in Germany.

The vaccination rates announced by the government were calculated through a system in which municipalities make registrations on the basis of inoculation vouchers.

As there is a delay in reporting vaccinations in some cases, the actual inoculation rates are believed to be higher than the tally shows.

The government hopes to finish administering two vaccine shots to all willing residents this month or in November. It plans to start giving booster shots, mainly to medical workers, before the end of this year.

https://www.japantimes.co.jp/news/2021/10/05/national/japan-vaccination-rate-60-percent/
 
Last edited:
Back
Top